Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 10/20 | 0.54 |
| ▸ | LPAR5 | Q9H1C0 | 9/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27540555 | 0.94 | HDAC1 (0.51) | LPAR1LPAR5HDAC1HDAC3HDAC2 | |
| SCHEMBL2595460 | 0.94 | HDAC1 (0.51) | LPAR1LPAR5HDAC1HDAC3HDAC2 | |
| SCHEMBL16682328 | 0.89 | ADRB3 (0.44) | LPAR1LPAR5HDAC1HDAC3HDAC2 | |
| SCHEMBL18067948 | 0.87 | ADRB3 (0.42) | LPAR1LPAR5HDAC1HDAC3HDAC2 | |
| SCHEMBL9823156 | 0.87 | HDAC1 (0.54) | LPAR1LPAR5HDAC1HDAC3HDAC2 | |
| SCHEMBL5739117 | 0.85 | LPAR1 (0.59) | LPAR1LPAR5ACHERCE1NPY5R | |
| SCHEMBL3151994 | 0.85 | HDAC3 (0.59) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL579800 | 0.85 | ALDH1A1 (0.52) | LPAR1LPAR5HDAC1HDAC3HDAC2 | |
| SCHEMBL14188105 | 0.85 | NPY5R (0.53) | LPAR1LPAR5HDAC1HDAC3HDAC2 | |
| SCHEMBL5703887 | 0.84 | HDAC1 (0.48) | LPAR1LPAR5HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | CHAPPELL MARK DONALD | 2008-08-28 | — | — | US | disclosed |
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | CHAPPELL MARK DONALD | 2008-08-28 | — | — | US | disclosed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| EP-1735268-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005092836-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | LPAR1 210/4885LPAR5 368/4885HDAC1 688/4885 |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | LPAR1 210/4885LPAR5 368/4885HDAC1 688/4885 |
| US-20110105571-A1 | Opioid Receptor Antagonists | OPRD1, OPRM1, OPRK1 | LPAR1 210/4885LPAR5 368/4885HDAC1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.